Document details

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial


Document Type Other
Language English
facebook logo  linkedin logo  twitter logo 
mendeley logo

Related documents

No related documents